Published Date: 13 Mar 2023
Canada: Long-term COVID-19 associated with psychiatric symptoms and cognitive impairment, research recently published in the journal Brain, Behavior,...
Read Full NewsAs part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.
At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.
As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.
Fibromyalgia in 2025: Year in Review
Rheumatoid Arthritis in 2025: Year in Review
Asthma in 2025: Year in Review
C3 Glomerulopathy in 2025: Year in Review
1.
In breast cancer patients with nodes positive, preoperative hydroxyprogesterone may enhance disease-free survival.
2.
EGFR Inhibitors for Lung Cancer Tied to Increased Keratitis Risk.
3.
What Comes After Cancer?
4.
Discovery of estrogen receptor 'switches' may aid breast cancer treatment
5.
Scientists hail the cervical cancer treatment as the most remarkable breakthrough in 20 years.
1.
Everything You Need To Know About Trichelemmal Cysts: Symptoms, Causes, Diagnosis And Treatment
2.
Refining AML Survival: Prognostic Factors, Therapies, and Stem Cell Strategies Reviewed
3.
Advancing Oncology Careers with Education, Workflow Tools, and Clinical Resources
4.
Optimizing Cancer Care: Multidisciplinary Approaches and Supportive Strategies
5.
Precision Oncology Advances: Neoantigen Therapies, TCR Strategies & Radiotherapy Innovations
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Lenalidomide and Dexamethasone (Rd) in MRD Negativity
2.
Efficient Management of First line ALK-rearranged NSCLC
3.
Current Scenario of Blood Cancer- A Conclusion on Genomic Testing & Advancement in Diagnosis and Treatment
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- A New Perspective
5.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation